Table 1.
Demographic characteristics of the allogeneic hematopoietic stem cell transplant recipients.
| Antibiotic therapy |
|||
|---|---|---|---|
| No, n (%) | Yes, n (%) | p-value | |
| Cohort/transplant center | |||
| HMR | 195 (74.7) | 181 (75.7) | 0.795 |
| CHUQ | 66 (25.3) | 58 (24.3) | |
| Gender | |||
| Female | 105 (40.2) | 94 (39.3) | 0.839 |
| Male | 156 (59.8) | 145 (60.7) | |
| Age group | |||
| <50 | 119 (45.6) | 121 (50.6) | 0.263 |
| >50 | 142 (54.4) | 118 (49.4) | |
| Stem cell source | |||
| Blood | 230 (88.1) | 187 (78.2) | 0.015* |
| Bone marrow | 26 (10.0) | 41 (17.2) | |
| Cord | 5 (1.9) | 11 (4.6) | |
| Donor | |||
| Related | 186 (71.3) | 149 (62.3) | 0.003** |
| Unrelated | 75 (28.7) | 90 (37.7) | |
| Intensity | |||
| Non-myeloablative | 160 (61.3) | 78 (32.6) | <0.001*** |
| Myeloablative | 101 (38.7) | 161 (67.4) | |
| Regimen | |||
| Fludarabine–cyclophosphamide | 104 (40.0) | 37 (15.5) | <0.001*** |
| Fludarabine–melphalan | 10 (3.8) | 13 (5.4) | |
| Fludarabine–busulfan(2) | 22 (8.5) | 26 (10.9) | |
| Fludarabine–busulfan(3) | 8 (3.1) | 0 (0.0) | |
| Fludarabine–busulfan(4) | 8 (3.1) | 7 (2.9) | |
| Busulfan–cyclophosphamide | 60 (23.1) | 77 (32.2) | |
| Cyclophosphamide–total body irradiation | 31 (11.9) | 49 (20.5) | |
| Cyclophosphamide–cytarabine–topotecan–busulfan | 6 (2.3) | 11 (4.6) | |
| Others | 11 (4.2) | 19 (8.0) | |
| Antibiotics | |||
| Ciprofloxacin | x | 157 (65.7) | |
| Trimethoprim–sulfamethoxazole | x | 29 (12.1) | |
| Levofloxacin | x | 18 (7.5) | |
| Moxifloxacin | x | 17 (7.1) | |
| Carbapenem | x | 16 (6.7) | |
| Vancomycin | x | 2 (0.8) | |
*
p < 0.05.
**
p < 0.01.
***
p < 0.001.